Close Menu

NEW YORK (GenomeWeb) – Natera went public late last week, raising $180 million in an initial public offering on the Nasdaq Global Select Market.

The San Carlos, California-based reproductive health molecular diagnostics firm offered 10 million shares of common stock at an offering price of $18 per share. The underwriters on the offering — Morgan Stanley, Cowen and Co., Piper Jaffray, R.W. Baird, and Wedbush Securities — have an over-allotment option to purchase an additional 1.5 million shares.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.